Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Metastatic Castrate-Resistant Prostate Cancer (mCRPC) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06046040
TmPSMA-02 in mCRPC
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Gender: MALE
Ages: 18 Years - Any
Updated: 2025-12-22
1 state
NCT07002320
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Gender: MALE
Ages: 18 Years - Any
Updated: 2025-12-04